Synthesis
One question, a cited answer.
Hylē breaks your question into sub-questions, retrieves papers and registries, and writes a synthesis in which every sentence points to its sources.
- Citations attached sentence by sentence
- Agreement and disagreement side by side
- Evidence gaps listed, not hidden
- S1Survival recordsPX-01 · Project file
- S2Dose–response assayPX-02 · Project file
- S3Survival in resistant tumoursnot found
Does the inhibitor’s survival benefit hold in resistant tumours?
At 30 mg/kg the inhibitor extends median survival from 24 to 51 days, but resistant cells need about 29 times more drug for the same effect.
Survival separates by dose across three arms S1. EC₅₀ rises from 14.2 nM in parental cells to 411 nM in the resistant line S2. There are no survival data for resistant tumours, so the benefit may not carry over S3.